Fibroblast growth factor 10 ameliorates renal ischaemia-reperfusion injury by attenuating mitochondrial damage

Lixia Yu1, Xiaojiao Yi1, Cailong Yu1

  • 1Department of Pharmacy, Xixi Hospital of Hangzhou, Zhejiang, China.

Insights

Fibroblast growth factor 10 (FGF10) protects against kidney injury from ischaemia-reperfusion (I/R). FGF10 reduces mitochondrial damage and improves survival, an effect blocked by 5-hydroxydecanoate (5-HD).

Area of Science:

  • Nephrology
  • Cell Biology
  • Biochemistry

Background:

  • Ischaemia-reperfusion (I/R) injury is a major cause of acute kidney injury (AKI).
  • The complex pathology of I/R injury involves oxidative stress, inflammation, autophagy, and apoptosis.
  • Fibroblast growth factor 10 (FGF10) and 5-hydroxydecanoate (5-HD) are implicated in kidney injury mechanisms.

Purpose of the Study:

  • To investigate the protective role of FGF10 against I/R-induced kidney injury in a rat model.
  • To elucidate the underlying mechanisms of FGF10's protective effects, focusing on mitochondrial function and ATP-sensitive potassium channels.

Main Methods:

  • Rats were subjected to renal I/R injury and treated with FGF10, 5-HD, or both.
  • Evaluated parameters included serum creatinine, apoptosis (TUNL assay), mitochondrial oxidative damage, mitochondrial membrane potential (MMP), and Kir6.2 expression.
  • The effect of the ATP-dependent potassium channel blocker 5-HD on FGF10's protection was assessed.

Main Results:

  • FGF10 treatment significantly reduced serum creatinine and tubular cell apoptosis in I/R-injured kidneys.
  • FGF10 ameliorated mitochondrial damage by reducing apoptosis, alleviating oxidative stress, and maintaining MMP.
  • FGF10's protective effects were compromised by 5-HD, indicating the involvement of mitochondrial KATP channels.

Conclusions:

  • FGF10 provides significant protection against I/R-induced kidney injury and improves survival.
  • The protective mechanism of FGF10 involves the attenuation of mitochondrial damage via KATP channel opening.
  • Targeting FGF10 and mitochondrial KATP channels may offer therapeutic strategies for AKI.